Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 3/20 | 0.46 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.46 |
| ▸ | SCN5A known ✓ | Q14524 | 2/20 | 0.46 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.42 |
| ▸ | SCN4A known ✓ | P35499 | 2/20 | 0.40 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.39 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.39 |
| ▸ | S1PR2 known ✓ | O95136 | 1/20 | 0.38 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.43 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4371426 | 0.98 | SOS1 (0.48) | SOS1SCN9AKCNH2SCN5AFFAR1 | |
| Hydrochloric Acid SCHEMBL5925413 | 0.89 | ALDH1A1 (0.48) | CA12CA1CA2CA9F2 | |
| Hydrochloric Acid SCHEMBL303900 | 0.86 | IDO1 (0.48) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL4847705 | 0.86 | ALDH1A1 (0.50) | CA12CA1CA2CA9F2 | |
| SCHEMBL8250 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL25275189 | 0.83 | CDK8 (0.46) | SOS1FFAR1FFAR4CA12CA1 | |
| Hydrochloric Acid SCHEMBL31229387 | 0.83 | CDK8 (0.46) | SOS1FFAR1FFAR4CA12CA1 | |
| Hydrochloric Acid SCHEMBL4373592 | 0.81 | PGR (0.49) | SCN9AKCNH2FFAR1FFAR4CA12 | |
| Bromide SCHEMBL20984751 | 0.81 | IDO1 (0.48) | CA12CA1CA2CA9ALDH1A1 | |
| Water SCHEMBL9206581 | 0.81 | IDO1 (0.48) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707816-A | Pyrazole hydrazide derivative containing diphenyl ether unit as well as preparation method and application thereof | 江苏海洋大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20230391790-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | TARO PHARMACEUTICALS INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| US-11773108-B2 | Indene derivatives useful in treating pain and inflammation | TARO PHARMACEUTICALS INC. (CA) | 2023-10-03 | — | — | US | disclosed |
| US-20220306645-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | TARO PHARMACEUTICALS INC. (CA) | 2022-09-29 | — | — | US | disclosed |
| US-11352367-B2 | Indene derivatives useful in treating pain and inflammation | TARO PHARMACEUTICALS INC. (CA) | 2022-06-07 | — | — | US | disclosed |
| CN-112543753-A | Indene derivatives useful for treating pain and inflammation | 塔罗制药公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3774738-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2021-02-17 | — | — | EP | disclosed |
| US-20210032264-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2021-02-04 | — | — | US | disclosed |
| WO-2019195777-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-10-10 | — | — | WO | disclosed |
| EP-1292577-B1 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO CELTIQUE SA (LU) | 2012-10-24 | — | — | EP | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-7078426-B2 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. (LU) | 2006-07-18 | — | — | US | disclosed |
| US-6919363-B2 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-07-19 | — | — | US | disclosed |
| US-20040002523-A1 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. | 2004-01-01 | — | — | US | disclosed |
| US-20020006947-A1 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | PURDUE PHARMA L.P. | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391790-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | IL1B, IL1A, LTB4R | SCN9A 1020/4885KCNH2 1434/4885SCN5A 1611/4885 |
| US-20210032264-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | IL1B, IL1A, LTB4R | SCN9A 1020/4885KCNH2 1434/4885SCN5A 1611/4885 |
| US-20220306645-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | IL1B, IL1A, LTB4R | SCN9A 985/4885KCNH2 1399/4885SCN5A 1629/4885 |
| US-11352367-B2 | Indene derivatives useful in treating pain and inflammation | IL1B, IL1A, LTB4R | SCN9A 1020/4885KCNH2 1434/4885SCN5A 1611/4885 |
| US-11773108-B2 | Indene derivatives useful in treating pain and inflammation | IL1B, IL1A, LTB4R | SCN9A 985/4885KCNH2 1399/4885SCN5A 1629/4885 |
| US-20040002523-A1 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | CACNA1I, GRIK5, SOD1 | SCN9A 318/4885KCNH2 285/4885SCN5A 10/4885 |
| US-20020006947-A1 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | GRIK5, CACNA1I, SOD1 | SCN9A 349/4885KCNH2 363/4885SCN5A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.